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Abstract: - Emerging and re-emerging viral infections are a big human concern and veterinary public health, and the development 
of antiviral drugs is urgently needed. The high cost of drug development limit the scalability of this antiviral approach. Drug 
repositioning or drug repurposing or drug profiling is the discovery of new applications for approved or failed drug. Drug 
repositioning is the development of new approved drug applications. The cost of bringing a medicine to the market is around one 
million which include clinical and preclinical trials. Repositioning of drugs help in cutting down costs as well as time involve in 
initial validation and authorization. Recently, there are so many drugs that have been tried and tested for COVID-19 treatment 
.One of these drugs is an antimalarial drug called as Hydroxychloroquine (HCQ). 
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I. INTRODUCTION 
Antiviral activities of HCQ made them potential candidate to 
study against viral diseases. In this study we are going to 
repurposed hydroxychloroquine(HCQ) for the treatment of 
viral diseases[1]. The standard method of product production 
requires vast quantities of time and energy before a compound 
is labored into the free market. Despite huge investments, a 
lead molecule often has minimal chances of entering the open 
market. The research molecule's itinerary remains 
unpredictable in its entire lifecycle. This situation causes new 
pharmaceutical companies to discover new drugs on dreams. 
Drug repositioning is one of the feasible choices for beginners 
in the area of new drug science. Drug discovery is the process 
of identification of biologically active small molecules 
against different disease conditions [4]. Classical drug 
research starts with the identification of disease targets, the 
detection of compounds and optimization, ADMET studies 
and finally to market. Developing a Single molecule may take 
10−17 years and the success rate can be as low as 0.01%. The 
global annual budgets of R&D became $ 130 billion with 
fewer new drugs. The numbers of new drugs or New 
Molecular Entities (NME) released in the market are 
decreased and there is acute pressure on the R&D circle to 
increase the number of candidate drugs in the late stage 
pipeline [5].  
Considering the large amount of investment that has been put 
recently in drug development only 23 drugs were approved in 
the year 2010, which is drastically less when compared to the 
drugs approved (53 drugs) a decade ago. These NMEs have 
to go through a number of pharmacokinetic and toxicity 
studies for their release into market. Molecules with potential 
drug like activities are evaluated simultaneously for their 
toxicity effects in cell and animal models. After a strenuous 
and systematic evaluation of drug activity and other 
properties, several drug like molecules may have to be 
dropped because of undesired bio-distribution and toxicity. A 
new concept called “drug repositioning” is being emerged in 
the pharmaceutical R&D circle. Drug repositioning is the 
discovery of new indications for approved drugs. Drug 
repositioning also known as drug profiling or drug 
repurposing. The cost of bringing a new medicine to the 
market is around one million which include clinical and 
preclinical trials. Drug repositioning procedure is generally 
performed during the phase of drug development to modify or 
extend an active molecule's distribution line. The COVD-19 
pandemic represents a significant challenge to the world from 
a health and financial perspective [2].The diseases has a high 
mortality rate and is very contagious, making it difficult to 
manage to manage .The complexity of COVID-19 is partially 
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evidenced by the disparity of symptoms from extremely mild 
in childrens and young adults to much more severe in older 
age group. We propose the urgent repositioning of an old drug 
hydroxychloroquine (HCQ) as an ideal antiviral prophylactic 
against COVID-19. This drug is capable of inhibiting the 
replication of some intracellular microorganism which 
includes viruses also. HCQ has the ability to block viral 
infection as it increase endosomal PH and also interfaces with 
the glycosylation of cellular receptor of SARS-COV .It is an 
antiviral agents as it is also known to inhibit quinine 
reductase-2, which is involved in sialic acid biosynthesis .It 
prevents the attachment of SARS-COV-2 to the target cells 
by interfacing with ACE 2 receptor glycosylation. 
So, the antiviral activities of HCQ made them potential 
candidate to study against viral diseases. Viruses are major 
risk for human health and economic well-being. [3] In this 
study we are going to repurposed hydroxychoroquine for the 
treatment of other viral diseases such as Ebola, Zika, 
influenza, chikungunya etc. 
II. METHODOLOGY 
Protein Selection: 
X ray crystallographic structure of all the targets protein was 
downloaded from PDB. 
Ligand Selection: 
Structure of HCQ was retrieved from PubChem database 
(http://pubchem.ncbi.nlm.nih.gov). HCQ was downloaded in 
SDF format and converted into PDB format file using SMILE. 
Molecular Docking: 
The 3D structure of targets was used for molecular docking 
with hydroxychloroquine using Autodock. 
III. RESULTS 
The results are described in the table and figure belows. 
Table.1. Showing binding free energy 
IV. CONCLUSION 
Recently, there are so many drugs that have been tried and 
tested for COVID-19 treatment. One of these drugs is an 
antimalarial drug called as hydroxychloroquine (HCQ).    
HCQ has antiflammatory properties and are used for immune 
disorder treatment such as diabetes, arthritis etc.  
Reports suggest that HCQ could be a candidate for COVID 
treatment .This drug is capable of inhibiting the replication of 
some intracellular microorganism which includes viruses 
also. HCQ has the ability to block viral infection as it increase 
endosomal PH and also interfaces with the glycosylation of  
Cellular receptor of SARS-COV .It is an antiviral agents as it 
is also known to inhibit quinine reductase-2, which is 
involved in sialic acid biosynthesis .It prevents the attachment 
of SARS-COV to the target cells by interfacing with ACE 2 
receptor glycosylation. 
PDB ID DISEASES DOCKING 
SCORE 
P03120 GENITAL WARTS -7.71 
Q77DJ5 EBOLA -5.41 
OO4350 LASSA FEVER -7.65 




015164 VIRAL MENINGILITIS -5.41 
P128823 VIRAL ENCEPHALITIS -7.65 
P06672 RABIES -11.73 
P08563 RUBELLA -8.70 
P0COE6 CHICKENPOX -6.89 
P07612 SMALLPOX -7.95 
P03300 POLIO -8.38 
076463 ROSEOLA -6.89 
P24941 CHICKENGUNYA -7.95 
Q03243 ROTAVIRUS -11.73 
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